Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients | Eli Lilly and Company Eli Lilly and Company
Eli Lilly launches program for employers to subsidize cost of obesity drug outside insurance statnews.com
Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S. CNBC
Zacks Market Edge Highlights: Caterpillar, Eli Lilly and Comfort Systems TradingView
Where Will Eli Lilly Stock Be in 10 Years? The Motley Fool
PFG Advisors Trims Stake in Eli Lilly and Company National Today
What Eli Lilly’s new employer platform could mean for access to weight-loss drugs Fast Company
Eli Lilly & Co (NYSE:LLY) Emerges as a Prime GARP Investment Candidate ChartMill
Baltimore Washington Financial Advisors Inc. Purchases 2,473 Shares of Eli Lilly and Company $LLY MarketBeat
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance Eli Lilly and Company
Vinva Investment Management Ltd Boosts Stake in Eli Lilly National Today
Statement: America’s leading role in biopharmaceutical innovation Eli Lilly and Company
Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer | Eli Lilly and Company Eli Lilly and Company
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas Eli Lilly and Company
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company Eli Lilly and Company
Lilly to acquire Orna Therapeutics to advance cell therapies | Eli Lilly and Company Eli Lilly and Company
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama | Eli Lilly and Company Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Eli Lilly and Company
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans Eli Lilly and Company
Lilly reports second-quarter 2025 financial results and raises guidance | Eli Lilly and Company Eli Lilly and Company
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility Eli Lilly and Company
Korea Investment CORP Increases Stake in Eli Lilly and Company National Today
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI Eli Lilly and Company
Cambria Investment Management L.P. Purchases 1,026 Shares of Eli Lilly and Company $LLY MarketBeat
Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials Eli Lilly and Company
Eli Lilly and Company $LLY Shares Sold by Orion Porfolio Solutions LLC MarketBeat
Deutsche Bank Maintains Buy on Eli Lilly and Company (LLY) March 06, 2026 Meyka
Eli Lilly Just Delivered Fantastic News to Investors The Motley Fool
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases Eli Lilly and Company
Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles CNBC
Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients | Eli Lilly and Company Eli Lilly and Company
LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound Eli Lilly and Company
Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment Eli Lilly and Company
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly and Company
Lilly announces plans to build $5 billion manufacturing facility in Virginia Eli Lilly and Company
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease | Eli Lilly and Company Eli Lilly and Company
Eli Lilly Becomes First Trillion-Dollar Health Company HealthDay
Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar CNBC
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes Eli Lilly and Company
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer Eli Lilly and Company